Pope Francis (Credit: X)
Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.
A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.
Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.
Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.
Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.
Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.
Credit: AI generated image
The Supreme Court of India has urged the All India Institute of Medical Sciences (AIIMS) to set up an expert panel
to examine how brain death is certified in India.
The apex Court has sought to know whether additional tests, such as electroencephalogram (EEG) and angiogram, are needed to declare a person brain dead.
A bench of Justices Vikram Nath and Sandeep Mehta was hearing a petition filed by Kerala-based medic and activist S Ganapathy, alleging malpractices in brain death certification, Times of India reported.
Ganapathy alleged that patients who may not be brain dead are sometimes declared so to facilitate organ donation. The petition also questioned the reliability of the apnea test—the standard method used to confirm brain death—calling it subjective and claiming that the legal requirement of video graphing the procedure is often not followed.
Brain death, technically referred to as brain-stem death, is the irreversible end of all brain activity.
In India, according to the Transplantation of Human Organs (THO) Act, 1994 (Subsection 6 of Section 3), 'brain stem death' refers to the stage at which all functions of the brain stem have permanently and irreversibly ceased.
This is to be certified by a 'Board of Medical Experts' consisting of:
(1) The medical superintendent (MS)/In-Charge of the hospital in which 'brain stem' death has occurred,
(2) a specialist,
(3) a neurologist or a neurosurgeon nominated by the MS, from a panel approved by the Appropriate Authority, and the doctor under whose care the 'brain- stem' death has occurred.
Amendments in the THO Act 2011 have allowed the selection of a surgeon/physician and an anesthetist, if an approved neurosurgeon or neurologist is unavailable.
“Brain stem death has to be certified by a panel of four independent doctors, including a neurologist or neurosurgeon, and confirmed twice with a minimum gap of six hours. The process is carried out with due diligence and seriousness,” Dr Manjari Tripathi, head of neurology at AIIMS, was quoted as saying.
“While the guidelines require the team of doctors to meet and declare brain death at least twice, we end up doing it sometimes three times for the patients. The current guidelines require various bedside tests for the declaration of brain death. It does not specify the need for tests such as an EEG or angiogram,” added Dr. Tripathi.
Experts said additional tests could add to the system burden. EEG is not routinely recommended for brainstem death certification, while an angiogram is used only in select cases where the apnea test cannot be performed. Globally, the apnea test remains the gold standard. These criteria are clearly laid down and cannot be altered, said experts.
The Indian Express reported that the lack of knowledge even among physicians is a significant challenge in India.
This leads to several patients never being officially declared and asked to be organ donors.
An AIIMS-led study, published in the journal Neurology India last year, found that more than half the doctors — including neurosurgeons, neurologists, and critical care specialists who are most commonly included in the certification process — did not receive any training on brain death certification at the time of their graduation.
Credit: iStock/Merck
The US Food and Drug Administration (FDA) has approved Merck's Idvynso (doravirine/islatravir), a new, once-daily pill for the treatment of HIV-1 infection in adults.
The two-drug single tablet replaces the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL).
The single tablet contains 100 mg doravirine and 0.25 mg islatravir. The FDA has approved it for adults on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.
“IDVYNSO combines islatravir, a next-generation NRTI with multiple mechanisms of action, including translocation inhibition, with doravirine, an NNRTI with an established efficacy and safety profile,” said Dr. Eliav Barr, senior vice president and chief medical officer, Merck Research Laboratories, in a statement.
The approval is based on data from two randomized, active-controlled, noninferiority trials. In the double-blind Trial 052, participants were randomly assigned to stay on Glilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide; 171 individuals) or switch to Idvynso (342 individuals).
Results showed that 1 per cent of participants in both groups had a viral load of ≥50 copies/mL at 48 weeks.
In the open-label Trial 051, participants were randomly assigned to stay on their oral antiretroviral therapy (ART) regimen (185 individuals) or switch to Idvynso (366 individuals).
Results showed that 1 per cent of participants who were switched to Idvynso had a viral load of ≥50 copies/mL at week 48 versus 5 per cent who continued on ART.
"As the only two-drug, non-integrase strand transfer inhibitor, tenofovir-free regimen, Idvynso expands therapeutic diversity beyond the currently available oral treatment options," Barr said.
"As the health needs of adults living with HIV change over time, Idvynso gives clinicians a new choice for HIV treatment."
What Is IDVYNSO? How Does It Work?
IDVYNSO is a fixed-dose combination of two medicines, doravirine with islatravir.
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
Islatravir is a potent, next-generation nucleoside analog reverse transcriptase inhibitor (NRTI) that blocks HIV-1 replication by multiple mechanisms, including:
According to the latest data from UNAIDS, 40.8 million people globally were living with HIV in 2024. Of these, 39.4 million were adults (15 years or older) and 1.4 million were children (0–14 years).
While 1.3 million people became newly infected with HIV in 2024, 630,000 died from AIDS-related illnesses.
About 87 per cent of all people living with HIV knew their HIV status, and 5.3 million people did not know that they were living with HIV.
Credit: AI generated image
The US eliminated measles in 2000, but since 2025, the highly infectious disease has spread to 45 states. As of early May 2026, the US has recorded 1,814 confirmed measles cases this year across 36 states. This follows a record-high 2,288 cases in 2025.
Now, the US Centers for Disease Control (CDC) has warned about additional measles cases ahead of the travel season.
The CDC urged public health agencies across the US to be prepared for more measles cases in the coming months.
"With continued measles transmission in areas across North America and expected increases in international and domestic travel and large events during spring and summer, additional measles cases are anticipated in the coming months," the agency said.
The guidance advised public health agencies to document and report details of each case of measles, including close contacts and locations visited while a person was infectious.
Active surveillance should be conducted to identify any additional suspected cases and quickly transport specimens for laboratory confirmation, the guidance said.
The agency also encouraged outreach to under-vaccinated communities and suggested using state-based syndromic surveillance systems to detect changes in health care–seeking behavior for fever and rash illnesses or signs of vitamin A toxicity.
Measles is a highly contagious virus that spreads through direct contact or through the air when an infected person coughs or sneezes. It is a vaccine-preventable disease that can cause devastating complications, including blindness, pneumonia, encephalitis, and long-term immune dysfunction.
Also read: Robert F. Kennedy Jr. Denies Link To Measles Outbreak At Senate Hearing
So far, there have been 24 new outbreaks reported in 2026, and 93 per cent of confirmed cases (1,688 of 1,814) are outbreak-associated (415 from outbreaks starting in 2026 and 1,273 from outbreaks that started in 2025).
In 2025, 48 outbreaks were reported, and 90 per cent of confirmed cases (2,065 of 2,288) were outbreak-associated.
According to researchers at Boston Children's Hospital, the US has missed four of the seven criteria for measles elimination status, which could put the country off track. More are at risk, they said.
In a Correspondence published in The Lancet, the researchers explained the missed indicators of measles elimination status in the US.
Read More: India Concerned Over Measles Outbreak, Action Underway: Dr N K Arora| Exclusive
The researchers believe these findings make a strong case for vaccinating children to protect them from a young age.
"Viral infections aren't all benign, and a measles infection, even when cleared, can result in lifelong problems," said Maimuna Majumder, from Boston Children's.
"Babies less than a year old are among those at greatest risk for severe complications, and the full impact on children exposed during the current outbreak may only show up years later," Majumder added.
© 2024 Bennett, Coleman & Company Limited